logo

Omeros Corp. (OMER)



Trade OMER now with
  Date
  Headline
5/24/2018 7:03:06 AM Omeros Announces Settlement Of Infringement Suit Against ANDA Filer Lupin
5/1/2018 3:35:57 PM Wedbush Reiterates Omeros Corp. (OMER) At Neutral With $19 Price Target
3/23/2018 7:31:05 AM Wedbush Is Lowering Omeros Corp. (OMER) FY18 Rev. Estimate To 9.5 M From 121.5 M
3/23/2018 7:30:40 AM Wedbush Is Cutting Omeros Corp. (OMER) Q4 18 Rev. Estimate To 3.4 M From 36.1 M
3/23/2018 7:30:28 AM Wedbush Is Lowering Omeros Corp. (OMER) Q3 18 Rev. Estimate To 2.6 M From 31.5 M
3/23/2018 7:29:47 AM Wedbush Is Lowering Omeros Corp. (OMER) Q2 18 Rev. Estimate To 2.0 M From 28.6 M
3/23/2018 7:29:13 AM Wedbush Is Lowering Omeros Corp. (OMER) Q1 19 Rev. Estimate To 1.5 M From 25.3 M
3/23/2018 7:28:36 AM Wedbush Is Lowering Omeros Corp. (OMER) FY18 Estimate To -2.03 From -0.24
3/23/2018 7:28:07 AM Wedbush Is Lowering Omeros Corp. (OMER) Q4 18 Estimate To -0.50 From 0.02
3/23/2018 7:27:51 AM Wedbush Is Lowering Omeros Corp. (OMER) Q3 18 Estimate To -0.51 From -0.05
3/23/2018 7:27:37 AM Wedbush Is Cutting Omeros Corp. (OMER) Q2 18 Estimate To -0.52 From -0.09
3/23/2018 7:27:16 AM Wedbush Is Cutting Omeros Corp. (OMER) Q1 18 Estimate To -0.51 From -0.13
3/23/2018 7:26:03 AM Wedbush Lowers Omeros Corp. (OMER) To Neutral From Outperform With $19 Down From $47 Price Target
2/15/2018 7:43:13 AM Omeros Announced New Results From Ongoing Phase 2 Study Of OMS721
1/22/2018 7:04:25 AM EMA Issues Orphan Drug Designation Positive Opinion For Omeros’ OMS721 In The Treatment Of IgA Nephropathy
1/4/2018 7:42:45 AM Wedbush Reiterates Omeros Corp. (OMER) At Outperform With $47 Price Target